Nurix Therapeutics, Inc. (NRIX) stock
NRIXNasdaqPharmaceutical PreparationsFiscal year ends November 30
Financials through Q3 FY2026, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 13, 2026Score 15/3073% below fair value
$15.48−0.12 (-0.77%)
Close on Nov 13, 2026Market cap $1.69BP/E 6.7Yield 0.00%
Nurix Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Nurix Therapeutics's operating cash flow for the twelve months ending Aug 31, 2026 was $379.31M. For fiscal 2025 it was -$249.47M. The highest annual figure on record is $601.00K in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Nov 30, 2025 | -$249.47M | – |
| FY2024 | Nov 30, 2024 | -$172.58M | – |
| FY2023 | Nov 30, 2023 | -$81.37M | – |
| FY2022 | Nov 30, 2022 | -$159.81M | – |
| FY2021 | Nov 30, 2021 | -$84.37M | – |
| FY2020 | Nov 30, 2020 | -$80.00K | -113.3% |
| FY2019 | Nov 30, 2019 | $601.00K | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026CQ3 2026 | Aug 31, 2026 | $615.63M | – |
| Q2 FY2026CQ2 2026 | May 31, 2026 | -$96.57M | – |
| Q1 FY2026CQ1 2026 | Feb 28, 2026 | -$71.91M | – |
| Q4 FY2025CQ4 2025 | Nov 30, 2025 | -$67.83M | – |
| Q3 FY2025CQ3 2025 | Aug 31, 2025 | -$57.39M | – |
| Q2 FY2025CQ2 2025 | May 31, 2025 | -$63.16M | – |
| Q1 FY2025CQ1 2025 | Feb 28, 2025 | -$61.09M | – |
| Q4 FY2024CQ4 2024 | Nov 30, 2024 | -$48.75M | -282.7% |
| Q3 FY2024CQ3 2024 | Aug 31, 2024 | -$42.18M | – |
| Q2 FY2024CQ2 2024 | May 31, 2024 | -$39.71M | – |
| Q1 FY2024CQ1 2024 | Feb 29, 2024 | -$41.95M | – |
| Q4 FY2023CQ4 2023 | Nov 30, 2023 | $26.69M | – |
| Q3 FY2023CQ3 2023 | Aug 31, 2023 | -$41.13M | – |
| Q2 FY2023CQ2 2023 | May 31, 2023 | -$18.47M | – |
| Q1 FY2023CQ1 2023 | Feb 28, 2023 | -$48.45M | – |
| Q4 FY2022CQ4 2022 | Nov 30, 2022 | -$37.96M | – |
| Q3 FY2022CQ3 2022 | Aug 31, 2022 | -$46.31M | – |
| Q2 FY2022CQ2 2022 | May 31, 2022 | -$32.91M | – |
| Q1 FY2022CQ1 2022 | Feb 28, 2022 | -$42.63M | -629.4% |
| Q4 FY2021CQ4 2021 | Nov 30, 2021 | -$30.91M | – |
| Q3 FY2021CQ3 2021 | Aug 31, 2021 | -$29.97M | – |
| Q2 FY2021CQ2 2021 | May 31, 2021 | -$31.54M | – |
| Q1 FY2021CQ1 2021 | Feb 28, 2021 | $8.05M | -80.3% |
| Q4 FY2020CQ4 2020 | Nov 30, 2020 | -$20.48M | – |
| Q3 FY2020CQ3 2020 | Aug 31, 2020 | -$6.14M | – |
| Q2 FY2020CQ2 2020 | May 31, 2020 | -$14.43M | – |
| Q1 FY2020CQ1 2020 | Feb 29, 2020 | $40.97M | – |
| Q4 FY2019CQ4 2019 | Nov 30, 2019 | -$12.75M | – |
See a number that looks wrong?